We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ID Biomedical has completed the final analysis of immune responses of adults
in its Phase II trial of StreptAvax vaccine, the company's subunit protein-based
vaccine against group A streptococcal diseases.
UCB Pharma's Celltech Antibody Research Centre of Excellence and Millennium
Pharmaceuticals have entered into an agreement in which they will collaborate
to research, develop and commercialize new antibody therapeutics generated
from two validated Millennium targets: a co-stimulatory molecule and a chemokine
receptor.
Pharmacyclics has presented additional preclinical data supporting the use
of novel compounds, based on the company's texaphyrin technology, to enhance
visualization of vulnerable atherosclerotic plaque, which is widely believed
to be a major cause of cardiovascular disease (CVD).
Advanced Magnetics and Cytogen have announced that clinical data published
in the December 2004 issue of Public Library of Science (PLoS) Medicine
shows for the first time the feasibility of computer-assisted lymph node staging
using Combidex, Advanced Magnetics' investigational molecular imaging agent.
A large clinical trial of a novel HIV vaccine has begun enrolling volunteers
at sites in North America, South America, the Caribbean and Australia, with
organizers seeking 1,500 participants.
Adventrx Pharmaceuticals has announced that the primary endpoint for response
rate and the secondary endpoint for safety were met in the first stage of its
Simon two-stage design Phase II trial using CoFactor to modulate the effect
of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer.